Pulmonary Tuberculosis Clinical Trials

Find Pulmonary Tuberculosis Clinical Trials Near You

A Multicenter, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of a Short-Course Treatment Regimen for Non-Severe Pulmonary Tuberculosis in Children (BRIGHT-Child TB)

Status: Recruiting
Location: See all (13) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The goal of this Phase II, multicenter, open-label, randomized controlled trial is to evaluate the efficacy and safety of short-course treatment regimens for children with non-severe, drug-susceptible pulmonary tuberculosis. The main questions it aims to answer are: * Do the 3-month bedaquiline, delamanid, contezolid, and pyrazinamide regimen (BDCZ) and the 4-month fixed-dose combination (FDC) regimen provide effective treatment, as measured by tuberculosis-free survival at 12 months after treatment initiation? * What are the safety profiles of the two short-course regimens, as measured by the incidence of grade 3 or higher adverse events? * How do the short-course regimens compare with the standard 6-month treatment regimen in terms of treatment success, treatment failure, recurrence, and tuberculosis-free survival during follow-up? Researchers will compare the 3-month BDCZ regimen and the 4-month FDC regimen with the standard 6-month treatment regimen to evaluate their efficacy and safety in children with non-severe, drug-susceptible pulmonary tuberculosis. Participants will be randomly assigned to one of three treatment groups and will receive the allocated regimen. They will undergo clinical assessments and safety monitoring during treatment, with follow-up to assess treatment outcomes, tuberculosis recurrence, and tuberculosis-free survival at 12, 18, and 24 months after treatment initiation.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 3 months
Maximum Age: 18
Healthy Volunteers: f
View:

• Children aged 3 months to 18 years.

• Body weight of at least 3 kg.

• Diagnosis of pulmonary TB according to the Chinese health industry standard WS 288-2017, Diagnosis of Tuberculosis, meeting the criteria for clinically diagnosed or bacteriologically confirmed tuberculosis.

• Symptomatic, non-severe tuberculosis, meeting the following criteria: Chest imaging findings consistent with pulmonary tuberculosis, with the investigator determining that the child is eligible for treatment of non-severe tuberculosis, and no cavitation or signs of miliary tuberculosis; Uncomplicated tuberculous pleurisy, without empyema, pneumothorax, or bronchopleural fistula; Intrathoracic lymph node tuberculosis without airway obstruction, or peripheral lymph node tuberculosis; Low bacillary burden, defined as a negative acid-fast bacilli (AFB) smear result from a respiratory specimen. A positive or negative Xpert MTB/RIF result is permitted. A negative Xpert MTB/RIF result may be accepted as an alternative to a negative smear result. Respiratory specimen culture results may be positive or negative.

• No previous anti-tuberculosis treatment, or previous treatment resulting in successful cure, with treatment having been completed more than 2 years before enrollment.

• Willingness to undergo HIV antibody testing.

• Willingness and ability to complete the assigned treatment and follow-up visits after treatment discontinuation.

• Written informed consent obtained from a parent or legal guardian.

• Residence and follow-up arrangements that allow the participant to complete the follow-up period within the study recruitment area.

Locations
Other Locations
China
Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province
RECRUITING
Fuzhou
Ganzhou Fifth People's Hospital
RECRUITING
Ganzhou
Guangzhou Chest Hospital
RECRUITING
Guangzhou
Guiyang Public Health Clinical Center
RECRUITING
Guiyang
Hangzhou Red Cross Hospital
RECRUITING
Hangzhou
The Children's Hospital, Zhejiang University School of Medicine
RECRUITING
Hangzhou
Shandong Public Health Clinical Center
RECRUITING
Jinan
Third People's Hospital of Liupanshui
RECRUITING
Liupanshui
Huashan Hospital
RECRUITING
Shanghai
The First Affiliated Hospital of Shihezi University
RECRUITING
Shihezi
The Fifth People's Hospital of Suzhou
RECRUITING
Suzhou
The Fourth People's Hospital of Qinghai Province
RECRUITING
Xining
Zunyi Infectious Diseases Hospital
RECRUITING
Zunyi
Contact Information
Primary
Tao Li
litaokc@vip.163.com
13816829726
Backup
Wenhong Zhang
zhangwenhong@fudan.edu.cn
52888123
Time Frame
Start Date: 2026-07-08
Estimated Completion Date: 2028-11-30
Participants
Target number of participants: 90
Treatments
Experimental: 4FDC
Experimental: 3BDCZ
Active_comparator: 2HRZ(E)/4HR
Related Therapeutic Areas
Sponsors
Leads: Huashan Hospital

This content was sourced from clinicaltrials.gov